CD19 and neoplasm: Importantly, purified NK cells armed with 161519 TriKE showed stronger lysis against CD19+ tumor cells, when compared with that of unarmed NK cells, indicating stronger targeting efficiency of 161519-armed NK cells and their potential for use in clinical cellular therapy.